Search results
Added:
3 years ago
With the widespread availability of non-invasive bedside assessment of ventricular function by echocardiography in the last two decades the paradigm of heart failure (HF), presumed to be usually due to an impaired left ventricular (LV) systolic function, has been challenged by the finding that about half of patients suffering from HF syndrome exhibit a normal LV ejection fraction (LVEF), and the…
View more
THT 2024
Start date:
Mar 06, 2024
End date:
Mar 04, 2024
Event
Added:
3 years ago
Heart failure is a complex clinical syndrome that results from a structural or functional cardiac abnormality. The prevalence of heart failure is likely to increase as the population ages and survival rates following myocardial infarction continue to improve.1 Morbidity and mortality rates are significant and relate to high healthcare costs in terms of hospital admissions and long-term care.2…
View more
Added:
3 years ago
Takotsubo syndrome is an acute reversible heart failure syndrome, which is increasingly recognised by coronary angiography for patients with acute ‘cardiac’ chest pain.1 It is a distinct disease entity from acute coronary syndrome, although the initial presentation has similar features to either ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction (NSTEMI). Early…
View more
Added:
3 years ago
Beta-blocker therapy remains one of the most fascinating issues in heart failure (HF) clinical practice. These agents, once absolutely contraindicated in patients with HF, have been shown to have the greatest beneficial effects on the patients' prognosis. They have radically changed the clinical course of HF, more than any other agent previously introduced, and are now the cornerstone of current…
View more
Added:
3 years ago
Interventricular conduction delay is common in patients with systolic heart failure (HF) and has been associated with a poor prognosis amongst these patients.1 Abnormal ventricular depolarization results in prolonged ventricular activation time and increased myocardial tension thus increasing myocardial oxygen consumption and decreasing ventricular diastolic filling time. In addition,…
View more
Added:
3 years ago
Q: What are the new treatment options in acute decompensated heart failure?
A: The new treatment options are the two recently introduced drugs, the calcium sensitiser, levosimendan which has been introduced in many European countries, and a B-type natriuretic peptide (BNP) Analogon nesiritide, utilised primarily in the US. This BNP causes basal dilation and improves diuresis.
Q: How do these…
View more
Added:
1 year ago
In this short summary video, Prof Giuseppe Rosano (St George's University Hospital, UK) shares his highlights from Heart Failure 2022 and his thoughts on the next frontiers of heart failure management.
Recorded at Heart Failure2022, Madrid.
View more
Added:
6 months ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more
Added:
3 years ago
Abstract
Heart failure with preserved left ventricular ejection fraction (HF-PEF), sometimes named diastolic heart failure, is a common condition most frequently seen in the elderly and is associated with arterial hypertension and left ventricular (LV) hypertrophy. Symptoms are attributed to a stiff left ventricle with compensatory elevation of filling pressure and reduced ability to increase…
View more
« First